BRCA1, BRCA2, and hereditary breast cancer

Breast Cancer: Prognosis, Treatment, and Prevention

Volumn , Issue , 2002, Pages 555-624

  Bove, Betsy A ^a   Dunbrack, Roland L ^a   Godwin, Andrew K ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 2542431689     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (368)

1. The BRCA1 Exon 13 Duplication Screening Group. The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. Am J Hum Genet 67: 207-212, 2000.
2. Anglican Breast Cancer Study Group (ABCSG). Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Br J Cancer 83(10): 1301-1308, 2000.
3. Abeliovich D, Kadwi L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching N, and Peretz T. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women. Am J Hum Genet 60: 505-514, 1997.
4. Altschul S, Madden T, Schaffer A, Zhang J, Zhang Z, Miller W, and Lipman D. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res25: 3389-3402, 1997.
5. Amos C, Frazier M, and Wang W. DNA pooling in mutation detection with reference to sequence analysis. Am J Hum Genet 66: 1689-1692, 2000.
6. Andersen T, Borresen A, and Moller P. A common BRCA1 mutation in Norwegian breast and ovarian cancer families. Am J Hum Genet 59: 486-487, 1996.
7. Anderson S, Schlegel B, Nakajima T, Wolpin E, and Parvin J. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nature Genet 19: 254-256, 1998.
8. Andres JI, Fan S, Turkel GJ, Wang J-A, Twu N-F, Yuan R-Q, Lamszus K, Goldberg ID, Rosen EM. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. Oncogene 16: 2229-2241, 1998.
9. Arason A, Jonasdottir A, Barkardottir R, Bergthorsson J, Teare M, Easton D, and Egilsson V. A population study of muations and LOH at breast cancer gene loci in tumours from sister pairs; two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland. J Med Genet 35: 446-449, 1998.
10. Ashley T, Plug A, Zu J, Solari A, Reddy G, Golub E, and Ward D. Dynamic changes in Rad51 distribution on chromatin during meiosis in male and female vertebrates. Chromosoma 104: 19-28, 1995.
11. Bandera C, Muto M, Schorge J, Berkowitz R, Rubin S, and Mod S. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol 92: 596-600, 1998.
12. Bannister A and Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature (London) 384: 641-643, 1996.
13. Barker D, Almeida E, Casey G, Fain P, Liao S, Masunaka I, Noble B, Kurosaki T, and Anton-Culver H. BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype. Genet Epidemiol 13: 595-604, 1996.
14. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Koverik J, and Lane DP. Patterns of expressions of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int J Cancer 46: 839-844, 1990.
15. Baumann P, Benson F, and West S. Human Rad51 protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. Cell 87: 757-766, 1996.
16. BCLC. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91: 1310-1316, 2000.
17. Belgrader P, Marino M, Lubin M, and Barany F. A multiplex PCR-ligase detection reaction assay for human identity testing. Genome Sci Technol 1: 77-87, 1996.
18. Bell D, Varley J, Szydlo T, Kang D, Wahrer D, Shannon K, Lubratovich M, Verselis S, Isselacker K, Fraumeni J, Birch J, Li F, Garber J, and Haber D. Heterozygous germline hCHK2 mutations in Li-Fraumeni syndrome. Science 286: 2528-2531, 1999.
19. Bellon S, Rodgers K, Schatz D, Coleman J, and Steitz T. Crystal structure of the RAG1 dimerization domain reveals multiple zinc-binding motifs including a novel zinc binuclear cluster. Nat Struct Biol 4: 586, 1997.
20. Bennett IC, Gattas M, and Teh BT. The genetic basis of breast cancer and its clinical implications. Aust NZ J Surg 69: 95-105, 1999.
21. Bennett LM, Haugen-Strano A, Cochran C, Brownlee H, Feidored F, and R. W. Isolation of the mouse homologue of BRCA1 and genetic mapping to mouse chromosome 11. Genomics 29: 576-581, 1995.
22. Berman D, Wagner-Costalas J, Schultz D, Lynch H, Daly M, and Godwin A. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185de-lAG-mutation kindreds. Am J Hum Genet 58: 1166-1176, 1996b.
23. Berman DB, Costalas J, Schultz DC, Grana G, Daly M, and Godwin AK. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and nonJewish individuals. Cancer Res 56: 3409-3414, 1996a.
24. Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H, Shindyalov I, and Bourne P. The Protein Data Bank. Nucleic Acids Res 28: 235-242, 2000.
25. Bertwistle D and Ashworth A. Functions of the BRCA1 and BRCA2 genes. Curr Opin Genet Dev 8: 14-20, 1998.
26. Bertwistle D, Swift S, Marston N, Jackson L, Crossland S, Crompton M, Marchall C, and Ashworth A. Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res 57: 5485 -5488, 1997.
27. Bianco T, Chenevix-Trench G, Walsh DCA, Cooper JE, and Dobrovic A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 21: 147-151, 2000.
28. Bick U. An integrated early detection concept in women with a genetic predisposition for breast cancer. Radiologe 37: 591-596, 1997.
29. Birch J, Heighway J, Teare M, Kelsey A, Hartley, AL, Tricker K, Crowther D, Lane D, and Santiba-nex-Koref M. Linkage studies in a Li-Fraumeni family with increased expression of p53 protein but no germline mutation in p53. Br J Cancer 70: 1176-1181, 1994.
30. Bishop DT. BRCA1 and BRCA2 and breast cancer incidence: A review. Ann Oncol 10(Suppl 6): 113-119, 1999.
31. Bochar D, Wang L, Beniya H, Kinwv A, Xue Y, Lane W, Wang W, Kashanchi F, and Shiekhattar R. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 102: 257-265, 2000.
32. Borressen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjord J, Ottestad L, Smith-Sorensen B, Hovig E, Malkin D, and Friend H. Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 52: 3234-3236, 1992.
33. Bowcock A. Breast cancer genes. Breast 3: 1-6, 1997.
34. Bower M, Cohen F, and Dunbrack R. Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. J Mol Biol 267: 1268-1282, 1997.
35. Boxhorn H and Eck S. Gene therapy for breast cancer. Hematol Oncol Clin North Am 12: 665-675, 1998.
36. Brunet JS, Ghadirian P, Rebbeck TR, Lerman C, Garber J, Tonin PN, Abrahamson J, Foulkes WD, Daly M, Wagner-Costalas J, Godwin AK, Olopade F, Moslehi R, Liede A, Futreal PA, Weber B, Lenoir GM, Lynch HT, and Narod SA. The effect of smoking on breast cancer incidence in BRCA1 and BRCA2 carriers. J Natl Cancer Inst 90: 761-766, 1998.
37. 2-terminal BRCA1 RING finger domain. J Biol Chem 273: 7795-7799, 1998.
38. Burke W, Daly M, Garber J, Botkin J, Kahn M, Lunch P, McTiernan A, Offit K, Perlman J, Petersen G, Thomson E, and Varricchio C. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277: 997-1003, 1997.
39. Cahill D, Lengauer C, Yu J, Riggins G, Willson J, Markowitz S, Kinzler K, and Vogelstein B. Mutations of mitotic checkpoint genes in human cancers. Nature 392: 300-303, 1998.
40. Caligo M, Ghimenti C, Cipollini G, Ricci S, Brunetti I, Marchetti V, Olsen R, Neuhausen S, Shattuck-Eidens D, Conte P, Skolnick M, and Bevilacqua G. BRCA1 germline mutational spectrum in Italian families from Tuscany: a high frequency of novel mutations. Oncogene13: 1483-1488, 1996.
41. Callebaut I and Mornon J-P. From BRCA1 to RAP1: A widespread BRCT module closely associated with DNA repair. FEBS Lett 400: 25-30, 1997.
42. Chamberlain J, Boehnke M, Frank TS, Kiousis S, Xu J, Guo S, Hauser E, Norum R, Helmbold E, Markel D, Keshavarzi S, Jackso C, Calzone K, Garber J, Collins F, and Weber B. BRCA1 maps proximal to D17S579 on chromosome 17q21 by genetic analysis. Am J Hum Genet52: 792-798, 1993.
43. Chapman MS and Verma IM. Transcriptional activation by BRCA1. Nature 382: 678-679, 1996.
44. Chehab N, Malikzay A, Appe M, and Halazonetis T. Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53. Genes Dev 14: 278-288, 2000.
45. Chen C-F, Li S, Chen Y, Chen P-L, Sharp ZD, and Lee W-H. The nuclear localization sequences of the BRCA1 protein interact with the importin-a subunit of the nuclear transport signal receptor. J Biol Chem 271: 32863-32868, 1996a.
46. Chen H, Lin R, Schiltz R, Chakravarti D, Nash A, Nagy L, Privalsky M, Nakatani Y, and Evans R. Nuclear receptor coactivaor ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CPB/p300. Cell 90: 569-580, 1997.
47. Chen J and Lindblom A. Germline mutation screening of the STK11/LKB1 gene in familial breast cancer with LOH on 19p. Clin Genet 57: 394-397, 2000.
48. Chen J, Silver DP, Walpita D, Canton SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, and Scully R. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 2: 317-328, 1998.
49. Chen J-J, Silver D, Cantor S, Livingston DM, and Scully R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 59: 1752s-1756s, 1999.
50. Chen P, Chen U, Bookstein R, and Lee W. Genetic mechanisms of tumor suppression by the human p53 gene. Science 250: 1576-1580, 1990.
51. Chen Y, Chen C-F, Riley DJ, Allred DC, Chen P-L, von Hoff D, Osborne CK, and Lee W-H. Aberrant subcellular localization of BRCA1 in breast cancer. Science 270: 789-791, 1995.
52. Chen Y, Farmer A, Chen C, Jones D, Chen P, con Hoff D, Osborne C, and Lee W. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner. Cancer Res 56: 3168-3172, 1996b.
53. Christians F and Hanawalt P. Inhibition of transcription and strand-specific DNA repair by alpha-amanitin in Chinese hamster ovary cells. Mutat Res 274: 93-101, 1992.
54. Claes K, Machackova E, DeVos M, Poppe B, DePaepe A, and Messiaen L. Mutation analysis of the BRCA1 and BRCA2 genes in the Belgian patient population and identification ofa Belgian founder mutation BRCA1 IVS5 + 3A > G. Dis Markers 15: 69-73, 1999.
55. Claus E, Risch N, and Thompson W. Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 131: 961-972, 1990.
56. Claus E, Risch H, and Thompson W. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 48: 232-242, 1991.
57. Claus E, Risch N, and Thompson W. Autosomal dominant inheritance of early-onset breast cancer: implications for risk prediction. Cancer 73: 643-651, 1994.
58. Collins FS. BRCA1-lots of mutations, lots of dilemmas. N Engl J Med 334: 186-188, 1996.
59. Connor F, Bertwistle D, Mee PJ, Ross GM, Swift S, Grigorieva E, Tybulewicz VLJ, and Ashworth A. Tumorigenesis and a DNA repair defect in mice with a truncating BRCA2 mutation. Nature Genet 17: 423-430, 1997a.
60. Connor F, Smith A, Wooster R, Stratton M, Dixon A, Campbell E, Tait T, Freeman T, and Ashworth A. Cloning, chromosomal mapping and expression pattern of the mouse Brca2 gene. Hum Mol Genet 6: 291-300, 1997b.
61. Cordeiro-Stone M, Hakhov A, Zaritskaya L, and Griffith J. Analysis od DNA replication forks encountering a pyrimidine dimer in the template to the leading strand. J Mol Biol 289: 1207-1218, 1999.
62. Cortez D, Wang Y, Qin J, and Elledge S. Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks. Science 286: 1162-1166, 1999.
63. Cotton RGH. Current methods of mutation detection. Mutat Res 285: 125-144, 1993.
64. Cotton RGH. Mutation detection. In: ExfordI: Publicherl, 1997 1, pp 58-67I.
65. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, and Weber BL. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336: 1409-1415, 1997.
66. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidens D, Godwin AK, Daly M, Radford DM, Sedlacek S, Rommens J, Simard J, Garber J, Merajver S, and Weber BL. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nature Genet 13: 123-125, 1996.
67. Cummings S, Norton L, Eckert S, and Thompson B. Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in postmenopausal women: two-year findings from the Multiple Outcomes of Raloxifene Evaluation Trial, (abstr). Proc Am Soc Clin Oncol17: 3, 1998.
68. Cummings S, Eckert S, Krueger K, Grady D, Powles T, Cauley J, Norton L, Nickelsen T, Bjarnason N, Morrow M, Lippman M, Black D, Glusman J, Costa A, and Jordan V. The effect of raloxifene on risk ofbreast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281: 2189-2197, 1999.
69. Dangel J, Wagner-Costalas J, Bove B, Vanderveer L, Daly M, Godwin, AK. Novel germline BRCA1 mutation in an African American with early-onset breast cancer. Hum Mutat, Mutation and polymorphism report #81. 1999.
70. Del Tito B, Poff H, Novotny M, Cartledge D, Walker R, Earl C, and Bailey A. Automated fluorescent analysis procedure for enzymatic mutation detection. Clin Chem 44: 731-739, 1998.
71. Deng C and Scott F. Role of the tumor suppressor gene BRCA1 in genetic stability and mammary gland tumor formation. Oncogene 19: 1059-1064, 2000.
72. Derijard B, Hibi M, Wu I, Barrett T, Su B, Deng T, Karin M, and Davis R. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025-1037, 1994.
73. Devilee P. BRCA1 and BRCA2 testing: Weighing the demand against the benefits. Am J Hum Genet 64: 943-948, 1999.
74. Dorum A, Moller P, Kamsteeg E, Scheffer H, Burton M, Heimdal K, Maehle L, Hovig E, Trope C, van der Muelen M, Buys C, te Meerman G. A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing. Eur J Cancer 33: 2390-2392, 1997.
75. Drucker L, Stackievitz R, Shpitz B, and Yarkoni S. Incidence of BRCA1 and BRCA2 mutations in Ashkenazi colorectal cancer patients: preliminary study. Anticancer Res 20: 559-561, 2000.
76. Dunbrack R. Comparative modeling of CASP3 targets using PSI_BLAST and SCWRL. Proteins Suppl (3): 81-87, 1999.
77. Dunbrack R and Karplus M. Backbone-dependent rotamer library for proteins. Application to side-chain prediction. J Mol Biol 230: 543-574, 1993.
78. Dunbrack R and Karplus M. Conformational analysis of the backbone-dependent rotamer preferences of protein sidechains. Nat Struct Biol 1: 334-340, 1994.
79. Dunbrack R and Cohen F. Bayesian statistical analysis of protein dise-chain rotamer preferences. Protein Sci 6: 1661-181, 1997.
80. Easton D, Ford D, and Peto J. Inherited susceptibility to breast cancer. Cancer Surv 18: 95-113, 1993a.
81. Easton D, Ford D, and Bishop D. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 265-271, 1995.
82. Easton D, Biship D, Ford D, and Crockford G. Genetic linkage analysis in familial breast and ovarian cancer: results for 214 families. The Breast Cancer Linkage Consortium. Am J Hum Genet 52: 678-701, 1993b.
83. Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA, McManus R, Neuhausen SL, Ford D, Wooster R, Cannon-Albright LA, Stratton MR, and Goldgar DE. Cancer Risks in two large breast cancer families linked to BRCA2 on chromosome 13q12-13. Am J Hum Genet 61: 120-128, 1997.
84. EBCTCG. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351: 1451-1467, 1998.
85. Edwards SM, Dunsmuir WD, Gilllett CE, Lakhani SR, Corbishley C, Young M, Kirby RS, Dearna-ley DP, Dowe A, Ardern-Jones A, Kelly J, Collaborators CBUFPCS, Spurr N, Barnes DM, and Eeles RA. Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. Int J Cancer 78: 1-7, 1998.
86. Eeles R, Stratton M, Goldgar D, and Easton D. The genetics of familial breast cancer and their practical implications. Eur J Cancer 30A: 1383-1390, 1994.
87. Egan KM, Newcomb PA, Longnecker MP, Trentham-Dietz A, Baron JA, Trichopoulos D, Stampfer MJ, and Willett WC. Jewish religion and risk of breast cancer. Lancet 347: 1645-1646, 1996.
88. El-Deiry WS, Harper JW, O’Conner PM, Velculescu VE, Canman CE, Jackman J, Peintenpol JA, Burrell M, Hill DE, Wang Y, Wilman KG, Mercer WE, Kastan MB, Konh KW, Elledge SJ, Kinzler KW, and Vogelstein B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169-1174, 1994.
89. Eliyahu D, Michalovitz D, Eliyahu D, Pinhasi-Kimhi O, and Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 1989: 8763-8767, 1989.
90. Esteller M. Epigenetic lesions causing genetic lesions in human cancer, promoter hypermethylation of DNA repair genes. Eur J Cancer 36: 2294-2300, 2000.
91. Fan S, Wang J-A, Yuan R-q, Ma YX, Meng Q, Erdos MR, Brody LC, Goldberg ID, and Rosen EM. BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 16: 3069-3082, 1998.
92. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos M, Pestell R, Yuan F, Auborn K, Goldberg I, and Rosen E. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 284: 1354-1356, 1999.
93. Favis R, Day J, Gerry N, Phelan C, Narod S, and Barany F. Universal DNA array detection of small insertions and deletions in BRCA1 and BRCA2. Nat Biotechnol 18: 561-564, 2000.
94. Feunteun J and Lenoir GM. BRCA1, a gene involved in inherited predisposition to breast and ovarian cancer. Biochim Biophys Acta 1242: 177-180, 1996.
95. Fiser A, Do R, and Sali A. Modeling of loops in protein structures. Protein Sci 9: 1753-1773, 2000.
96. Fisher B and Constantino J. Highlights of the NSABP breast cancer prevention trial. Cancer Control 4: 78-86, 1997.
97. FitzGerald M, MacDonald D, Krainer M, Hoover I, O’Neil E, Unsal H, Silva-Arrieto S, Findelstein D, Beer-Romero P, Englert C, Sgroi D, Smith B, Younger J, Garter J, Duda R, Mayzel K, Isselbacher K, Friend S, and Haber D. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 334: 143-149, 1996.
98. Fodde Rand Losekoot M. Mutation detection by denaturing gradient gel electrophoreses (DGGE). Hum Mutat 3: 83-94, 1994.
99. Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, Brower ST, and Eng CM. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet 63: 45-51, 1998.
100. Ford D, Easton D, and Peto J. Estimate of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57: 1457-1462, 1995.
101. Ford D, Easton D, Bishop D, Narod S, and Goldgar D. Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343: 692-695, 1994.
102. Ford D, Easton D, Stratton M, Narod S, Goldgar D, Devilee P, DT B, Weber B, Lenoir G, ChangClaude J, Sobol H, Teare M, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck T, Tonin P, Newhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder A, Gayther S, Birch J, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamann U, Haites N, Scott R, Maugard C, Vasen H, Seitz S, Cannon-Albright L, Schofield A, Zelada-Hedman M, and Consortium BCL. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 62: 676-689, 1998.
103. Fornander T, Rutqvist L, Cedermark B, Glas U, Mattsson A, Silfversward C, Skoog L, Somell A, Theve T, Wiling N, Askergren J, and Hjalmar M. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117-120, 1989.
104. Frebourg T, Barbier N, Yan Y, Garber J, Dreyfus M, Fraumeni J, Li F, and Friend S. Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 56: 608-615, 1995.
105. Friedberg E, and Gerlach, V. Novel DNA polymerases offer clues to the molecular basis of mutagenesis. Cell 98: 413-416, 1999.
106. Friedberg E, Waleker G, and Siede WE: DNA repair and mutagenesis. Washington, DC: ASM Press, 1995, p 1.
107. Fuks F, Milner J, and Kouzarides T. BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 17: 2531-2534, 1998.
108. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harchman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, Eddington K, McClure M, Frye C, Weaver-Feldhaus J, Ding W, Gholami Z, Soderkvist P, Terry L, Jhanwar S, Berchuck A, Inglehart J, Marks J, Ballinger G, Barrett J, Skolnick M, Kamb A, and Wiseman R. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266: 120-122, 1994.
109. Gad S, Scheumer M, Pages-Berhouet S, Caux-Montcoutier V, Bensimon A, Aurias A, Pinto M, Stoppa-Lyonnet D. Indentification of a large rearrangement of the BRCA1 gene using colour bar code on combed DNA in an American breast/ovarian cancer family previously studied by direct sequencing. J Med Genet 38: 388-392, 2001.
110. Gail M, Brinton L, Byar D, Corle D, Green S, Schairer C, and Mulvihill J. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81: 1879-1886, 1989.
111. Gannon J and Lane D. Interactions between SV40 T antigen and DNA polymerase alpha. New Biol 2: 84-92, 1990.
112. Gao Q, Neuhausen S, Cummings S, Luce MC, and Olopade F. Recurrent germline BRCA1 mutations in extended African American families with early-onset breast cancer. Am J Hum Genet 60: 1233-1236, 1997.
113. Gao Q, Tomlinson G, Cummings S, Fackenthal J, Schumm P, and Olopade O. Prevalence of BRCA1 and BRCA2 mutations among clinic-based African American families with breast cancer. Hum Genet 107: 186-191, 2000.
114. Garber J and Patenaude A. Ethical, social, and counseling issues in hereditary cancer susceptibility. Cancer Surv 25: 381-397, 1995.
115. Garret P, Hulka B, Kim Y, and Farber R. HRAS protooncogene polymorphism and breast cancer. Cancer Epidemiol Biomarkers Prev 2: 131-138, 1993.
116. Gayther S, Mangion J, Russell P, Seal S, Barfoot R, Ponder B, Stratton M, and Easton D. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nature Genet 15: 103-105, 1997.
117. Gayther S, Warren W, Mazoyer S, Russell P, Harrington P, Chiano M, Seal S, Hamoudi R, van-Rensburg E, Dunning A, Love R, Evans G, Easton D, Clayton D, Stratton M, and Ponder B. Germline mutations of the BRCA1 gene in breast/ovarian cancer families: evidence for a genotype/phenotype correlation. Nature Genet 11: 428-433, 1995.
118. Gayther S, de Foy K, Harrington P, Pharoah PDP, Dunsmuir WD, Edwards SM, Gillett C, Ardern-Jones A, Dearnaley DP, Easton D, Ford D, Shearer R, Kirby RS, Dowe A, Delly J M S, Ponder B, Barnes D, and Eeles R. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. Cancer Res 60: 4513-4518, 2000.
119. Gerry N, Witowski N, Day J, Hammer R, Barany G, and Barany F. Universal DNA microarray method for multiplex detection of low abundance point mutations. J Mol Biol 292: 251-262, 1999.
120. Glavac D and Dean M. Optimization of the single-strand conformation polymorphism (SSCP) technique for detection of point mutations. Hum Mutat 2: 404-414, 1993.
121. Godard J, Dodds W, Phillips J, and Scanlon G. Peutz-Jeghers syndrome: clinical and roentgeno-graphic features. Am J Roentgenol Radium Ther Nucl Med 113: 316-324, 1971.
122. Goggins M, Hruban R, and Kern S. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 156: 1767-1771, 2000.
123. Gorski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Gronwald J, Pluzanska A, Bebenek M, Fischer-Maliszewska L, Grzybowska E, Narod S, and Lubinski J. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 66: 1963-1968, 2000.
124. Gosse-Brun S, Sauvaigo S, Daver A, Lortholoary A, Larra F, Bignon Y, and Bernard-Gallon D. Sjpecific H-Ras minisatellite alleles in breast cancer susceptibility. Anticancer Res 19: 5191-5196, 1999.
125. Gowen LC, Johnson BL, Latour AM, Sulik KK, and Koller BH. BRCA1 deficiency results in early embryonic lethality characterized by neuroepithelial abnormalities. Nature Genet 12: 191-194, 1996.
126. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, and Leadon SA. BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 281: 1009-1012, 1998.
127. Grann V, Whank W, Jacobson J, Heirjan D, Antman K, and Neugut A. Benefits and costs of screening Ashkenazi Jewish women for BRCA1 and BRCA2. J Clin Oncol 17: 494-500, 1999.
128. Gudas JM, Nguyen H, and Cowan K. Hormone-dependent regulation of BRCA1 in human breast cancer cells. Cancer Res 55: 4561-4565, 1995.
129. Hakansson S, Johannsson O, Johansson U, Sellberg G, Loman N, Gerdes A-M, Holmberg E, Dahl N, Pandis N, Kristoffersson U, Olsson H, Borg A. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandanavian familial breast cancer. Am J Hum Genet 60: 1068-1078, 1997.
130. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J, and Mak TW. The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse. Cell 85: 1009-1023, 1996.
131. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, and King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250: 1684-1689, 1990.
132. Hanssen AMN and Fryns JP. Cowden syndrome. J Med Genet 32: 117-119, 1995.
133. Hartge P, Struewing JP, Wacholder S, Brody LC, and Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64: 963-970, 1999.
134. Hartmann L, Schaid D, Woods J, Crotty T, Myers J, Arnold P, Petty P, Sellers T, Johnson J, McDonnell S, Frost M, and Jenkins R. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340: 77-84, 1999.
135. Hastings P, Quah S, and von Borstel R. Spontaneous mutations by mutagenic repair of spontaneous lesions in DNA. Nature 264: 719-722, 1976.
136. Hayes F, Cayanan C, Barilla D, and Monteiro AN. Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation. Cancer Res60: 2411-2418, 2000.
137. Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A, Bignell G, Warren W, Aminoff M, Hoglund P, Jarvinen H, Kristo P, Pelin K, Ridanpaa M, Salovaara R, Toro T, Bodmer W, Olschwang S, Olsen A, Stratton M, de la Chapelle A, and Aaltonen L. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391: 184-187, 1998.
138. Hisada M, Garber A, Fung C, Fraumeni J, and Li F. Mulitple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 90: 606-611, 1998.
139. Hopper J, Southey M, Dite G, Jolley D, Giles G, McCredie M, Easton D, and Venter D. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev 8: 741-747, 1999.
140. Hosking L, Trowsdale J, Nicolai H, Solomon E, Foulkes W, Stamp G, Signer E, and Jeffreys A. A somatic BRCA1 mutation in an ovarian tumour. Nat Genet 9: 343-344, 1995.
141. Hoskins K, Stopfer J, Calzone K, Merajver S, Rebbeck T, Barber J, and Weber B. Assessment and counseling for women with a family history of breast cancer: a guide for clinicians. JAMA 273: 577-585, 1995.
142. Houlston R and Damato B. Genetic predisposition to ocular melanoma. Eye 13: 43-46, 1999.
143. Hu Y-F, Miyake T, Ye Q, and Li R. Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain. J Biol Chem 275(52): 40910-40915, 2000.
144. Hubert A, Peretz T, Manor O, Kadwi L, Wienberg N, Lerer I, Sagi M, and Abeliovich D. The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 65: 921-924, 1999.
145. Huusko P, Paakkonen K, Launonen V, Poyhonen M, Blanco G, Kauppila A, Puistola U, Kiviniemi H, Kujala M, Leisti J, and Winqvist R. Evidence of founder mutations in Finnish BRCA1 and BRCA2 families. Am J Hum Genet 62: 1544-1548, 1998.
146. Huyton T, Bates PA, Zhang X, Sternberg MJE, and Freemont PS. The BRCA1 C-terminal domain: structure and function. Mutat Res 460: 319-332, 2000.
147. Inoue R, Fukutomi T, Ushijima T, Matsumoto Y, Sugimura T, and Nagao M. Germline mutation of BRCA1 in Japanese breast cancer families. Cancer Res 55: 3521-3524, 1995.
148. Itoh H, Houlston R, Harocopos C, and Slack J. Risk of cancer death in first-degree relatives of patients with hereditary non-polyposis cancer syndrome (Lynch type II): a study of 139 kindreds in the United Kingdom. Br J Surg 77: 1367-1370, 1990.
149. Jatoi I. Breast cancer screening. Am J Surg 177: 518-524, 1999.
150. Jensen D, Proctor M, Marquis S, Gardnet H, Ha S, Chodosh L, Ishov A, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz D, Wilkinson K, Maul G, Barlev N, Berger S, Prendergast G, and Rauscher F. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16: 1097-1112, 1998.
151. Jin S, Zhao H, Fan F, Blanck P, Fan W, Colchagie A, Fornace A, and Zhan Q. BRCA1 activation of the GADD45 promoter. Oncogene 19: 4050-4057, 2000.
152. Jin Y, Zu ZL, Yang M-CW, Wei F, Ayi T-C, Bowcock AM, and Baer R. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. Proc Natl Acad Sci USA 94: 12075-12080, 1997.
153. Johannsson O, Ostermeyer E, Hakansson S, Friedman L, Johansson U, Selberg G, Brondum-Niel-sen K, Sele V, Olsson H, King M, and Borg A. Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet 58: 441-450, 1996.
154. Kainu T, Juo S, Desper R, Schaffer A, Gillanders E, Rozenblum E, Freas-Lutz D, Weaver D, Stephan D, Bailey-Wilson J, Kallioniemi O, Tirkkonen M, Syrjakoski K, Kuukasjarvi T, Koi-visto P, Karhu R, Holli K, Arason A, Johannesdottir G, Bergthorsson JT, Hohannsdottir H, Egilsson V, Barkardottir R, Johannsson O, Haraldsson K, Sandberg T, Holmberg E, Gronberg H, Olsson H, Borg A, Vehmanen P, Eerola H, Heikkila P, Pyrhonen S, and Nevenlinna H. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci USA 97: 9603-9608, 2000.
155. Kanemura S, Tsuji I, Ohuchi N, Takei H, and Koibuchi Y. A case control study on the effectiveness of breast cancer screening by clinical examination in Japan. Jpn J Cancer Res 90: 607-613, 1999.
156. Katagira T, Saito H, Shinohara A, Ogawa H, Kamada N, Nakamura Y, and Miki Y. Multiple possible sites of BRCA2 interacting with DNA repair protein RAD51. Genes Chromosomes Cancer 21: 217-222, 1998.
157. Katsama A, Sourvinos G, Zachos G, and Spandidos D. Allelic loss at the BRCA1, BRCA2, and TP53 loci in human sporadic breast carcinoma. Cancer Lett 150: 165-170, 2000.
158. Kerangueven F, Essioux L, Dib A, Noguchi T, Allione F, Geneix J, Longy M, Lidereau R, Eisinger F, Pebusque M, Jacquemier J, Bonaiti-Pellie C, Sobol H, and Birnbaum D. Loss of hererozy-gosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. Oncogene 10: 1023-1026, 1995.
159. Khanna M, Park P, Zirvi M, Cao W, Picon A, Day J, Paty P, and Barany F. Multiplex PCR/LDR for detection of K-ras mutations in primary colon tumors. Oncogene 18: 27-38, 1999.
160. Khoo U-S, Ozcelik H, Cheung ANY, Chow LWC, Ngan HYS, Done SJ, Liang ACT, Chan VWY, Au GKH, Ng W-F, Poon CSP, Leung Y-F, Loong F, Ip P, Chan GSW, Andrulis IL, Lu J, and Ho FCS. Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer. Oncogene 18: 4643-4646, 1999.
161. Kleihues P, Schauble B, zur Hausen A, Esteve J, and Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 150: 1-13, 1997.
162. Ko LJ and Prives C. P53: puzzle and paradigm. Genes Dev 10: 96-99, 1996.
163. Kowalczykowski S. Biochemistry of genetic recombination: energetics and mechanism of DNA strand exchange. Annu Rec Biophys Chem 20: 539-575, 1991.
164. Krontiris T, Devlin B, Karp D, Robert N, and Risch N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 329: 517-523, 1993.
165. Kulinski J, Besack D, Oleykowski CA, Godwin AK, and Yeung AT. CEL I enzymatic mutation detection assay. Benchmarks Biotechniques 29: 44-48, 2000.
166. Laken SJ, Petersen GM, Gruber SB, Oddoux C, Ostrer H, Giardiello FM, Hamilton SR, Hampel H, Markowitz A, Klimstra D, Jhanwar S, Winawer S, Offit K, Luce MC, Kinzler KW, and Vogelstein B. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nature Genet 17: 79-83, 1997.
167. Lakhani S, Easton D, Stratton M, and BCLC. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349: 1505-1510, 1997.
168. Lakhani S, Gusterson B, Jacquemier J, Sloane J, Anderson T, van de Vijver M, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, Steel C, Haites N, Scott R, Goldgar D, Neuhausen S, Day P, Ormiston W, McManus R, Scherneck S, Ponder B, Futreal P, Peto J, Stoppa-Lyonnet D, Bignon Y, Struewing J, Bishop D, Klijn J, Devilee P, Cornelisse C, Lasset C, Lenoir G, Barkardottir R, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Easton D, and Stratton M. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6: 782-789, 2000.
169. Lakhani S, Jacquemier J, Sloane J, Gusterson B, Anderson T, van deVijver M, Farid L, Venter D, Antoniou A, Storfer-Isser A, Smyth E, Steel C, Haiter N, Scott R, Godger D, Heuhausen S, Day P, Ormisoton W, McManus R, Scherneck S, Ponder B, Ford D, Peto J, Stoppa-Lyonnet D, Bignon Y, Streuwing J, Spurr N, Biship D, Lkijn J, Devilee P, Cornelisse C, Lasset C, Lenoir G, Bardardottir R, Egilsson V, Hamann U, Chang-Claude J, Sobol H, Weber B, Stratton M, and Easton D. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90: 1138-1145, 1998.
170. Lal G, Liu G, Shmocker B, Kaurah P, Ozcelik H, Narod S, Redston M, and Gallinger S. Inherited predisposition to pancreatic adenocarcinoma: role offamily history and germline p16, BRCA1, and BRCA2 mutations. Cancer Res 60: 409-416, 2000.
171. Lancaster J, Wooster R, Mangion J, Phelan C, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman R, Berchuck A, Iglehart J, Marks J, Ashworth A, Stratton M, and Futreal P. BRCA2 mutations in primary breast and ovarian cancers. Nature Genet 13: 238-240, 1996.
172. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, and Leder P. Expression of BRCA1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. Genes Dev 9: 2712-2722, 1995.
173. Langston AA, Stanford JL, Wicklund KG, Thompson JD, Blazej RG, and Ostrander EA. Germline BRCA1 mutations in selected men with prostate cancer. Am J Hum Genet 58: 881-885, 1996.
174. Larson J, Tonkinson L, and Lai M. BRCA1 mutation alters G2-M cell cycle control in human mammary epithelial cells. Cancer Res 57: 3351-3355, 1997.
175. Le Page F, Randrianarison V, Marot D, Cabannes J, Perricaudet M, Feunteun J, and Sarasin A. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine leasio in human cells. Cancer Res 60: 5548-5552, 2000.
176. Leadon SA and Lawrence D. Preferential repair of DNA damage on the transcribed strand of the human metallothionein genes requires RNA polymerase II. Mutat Res 255: 67-78, 1991.
177. Leadon SA and Lawrence C. Strand-selective repair of DNA damage in the yeast GAD7 gene requires RNA polymerase II. J Biol Chem 267: 23175-23182, 1992.
178. Lee H, Trainer A, Friedman L, Thistlethwaite F, Evans M, Ponder B, and Venkitaraman A. Mitotic checkpoint inactivation fosters transformation in cells lacking the breast cancer susceptibility gene, Brca2. Mol Cell 4: 1-10, 1999.
179. Lee J-S, Collins KM, Brown AL, Lee C-H, and Chung JH. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. Nature 404: 201-204, 2000.
180. Lehrer S, Fodor F, Stock RG, Stone NN, Eng C, Song HK, and McGovern M. Absence of 185de-lAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 78: 771-773, 1998.
181. Lerman C, Sea J, Balshem A, and Audrain J. Interest in genetic testing among first-degree relatives of breast cancer patients. Am J Med Genet 57: 385-392, 1995.
182. Li C, Larsson C, Futreal A, Lancaster J, Phelan C, Aspenblad U, Sundelin B, Liu Y, Ekman P, Auer G, and Bergerheim USR. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene 16: 481-487, 1998.
183. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, CmCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, and Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 13: 1943-1947, 1997.
184. Li RP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, and Miller RW. A cancer family syndrome in twenty-four kindreds. Cancer Res 48: 5358-5362, 1988.
185. Lidereau R, Escot C, Theillet C, Champeme M, Brunet M, Best J, and Callahan R. High frequency of rare alleles of the human cj-Ha-ras-1 protooncogene in breast cancer patients. J Natl Cancer Inst 77: 697-701, 1986.
186. Liede A, Cohen B, Black D, Davidson R, Renwidk A, Hoodfar E, Olopade O, Micek M, Anderson V, DeMey R, Fordyce A, Warner E, Dann JL, King MC, Weber B, Narod S, and Steel C. Evidence of a founder BRCA1 mutation in Scotland. Br J Cancer 82: 705-711, 2000.
187. Lim DS and Hasty P. A mutation in mouse Rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. Mol Cell Biol 16: 733-743, 1996.
188. Lipshutz R, Fodor S, Gingeras T, and Lockhart D. High density synthetic ologonucleotide arrays. Nature Genet Suppl 21: 20-24, 1999.
189. Liu C-Y, Flesken-Nikitin A, Li S, Zeng Y, and Lee W-H. Inactivation of the mouse BRCA1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev 10: 1835-1843, 1996.
190. Lovering R, Hanson IM, Borden KLB, Martin S, O’Reilly NJ, Evan GI, Rahman D, Pappin DJC, Trowsdale J, and Freemont PS. Identification and preliminary characterization of a protein motif related to the zinc finger. Proc Natl Acad Sci USA 90: 2112-2116, 1993.
191. Ludwig T, Chapman D, Papaioannou V, and Efstratiadis A. Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 11: 1226-1241, 1997.
192. Lynch H and Krush A. Carcinoma of the breast and ovary in three families. Surg Gynecol Obstet 133: 644-648, 1971.
193. Lynch H, Smyrk T, and Lynch J. Overview of natural history, pathology, molecular genetics and management of HNPCC (Lynch syndrome). Int J Cancer 69: 38-43, 1996.
194. Lynch H, Fusaro R, Lemon S, Smyrk T, and Lynch J. Survey of cancer genetics: genetic testing implications. Cancer 80: 523-532, 1997.
195. Lynch H, Krush A, Lemon H, Kaplan A, Condit P, and Bottomley R. Tumor variation in families with breast cancer. JAMA 222: 1631-1635, 1972.
196. Lynch H, Guirgish H, Albert S, Brennan M, Lynch J, Kraft C, Pocekay D, Vaughns C, and Kaplan A. Familial association of carcinoma of the breast and ovary. Surg Gynecol Obstet 138: 717-724, 1974.
197. Lynch HR, Harris RE, Guirgis HA, Maloney K, Carmody LL, and Lynch JF. Familial association of breast/ovarian carcinoma. Cancer 41: 1543-1549, 1978.
198. Lynch HT, Fain PR, Golgar D, Albano WA, Mailliard JA, and McKenna P. Familial breast cancer and its recognition in an oncology clinic. Cancer 47: 2730-2739, 1981.
199. Lynch HT, Watson P, Tinley S, Snyder C, Durham C, Lynch J, Kirnarsky Y, Serova O, Lenoir G, Lerman C, and Narod SA. An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer. Cancer Genet Cytogenet 109: 91-98, 1999.
200. Malins D and Haimanot R. Major alterations in the nucleotide structure of DNA in cancer of the female breast. Cancer Res 51: 5430-5432, 1991.
201. Malins D, Holmes E, Polissar N, and Gunselman S. The etiology of breast cancer. Characteristic alteration in hydroxyl radical-induced DNA base lesions during oncogenesis with potential for evaluating incidence risk. Cancer 71: 3036-3043, 1993.
202. Malkin D, Li F, Strong L, Fraumeni J, Nelson C, Kim D, Kassel J, Gryka M, Bisehoff F, Tainsky M, and Friend S. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233-1238, 1990.
203. Malone K, Daling J, Neal CL, Suter N, O’Brien C, Cushing-Haugen K, Jonasdottir T, Thompson JD, and Ostrander EA. Frequency of BRCA1 /BRCA2 mutations in a population-based sample of young breast carcinoma cases. Cancer 88: 1393-1402, 2000.
204. Mancini DN, Rodenhiser DI, Ainsworth PJ, O’Malley FP, Singh SM, Xing W, and Archer TK. CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene 16: 1161-1169, 1998.
205. Marcue J, Watson P, Page D, and Lynch H. Pathology and heredity of breast cancer in younger women. J Natl. Cancer Inst Monograph 16: 23-34, 1994.
206. Markoff A, Savov A, Vladimirov V, Bogdanaova N, Kremensky I, and Ganev V. Optimization of single-strand conformation polymorphism analysis in the presence of polyethylene glycol. Clin Chem 43: 30-33, 1997.
207. Markoff A, Sormbroen H, Bogdanova N, Preisler-Adams S, Ganev V, Dworniczak B, and Horst J. Comparison of conformation-sensitive gel electrophoresis and single-strand conformation polymorphism analysis for detection of mutations in the BRCA1 gene using optimized conformation analysis protocols. Eur J Hum Genet 6: 145-150, 1998.
208. Marmorstein LY, Ouchi T, and Aaronson SA. The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci USA 95: 13869-13874, 1998.
209. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin G-Y, Abel KJ, Weber BL, and Chodosh LA. The developmental pattern of BRCA1 expression implies a role in differentiation of the breast and other tissues. Nature Genet 11: 17-26, 1995.
210. Mazoyer S, Dunning AM, Serova O, Dearden J, Puget N, Healey C, Gayther S, Mangion J, Stratton M, Lynch H, Goldgar D, Ponder B, and Lenoir G. A polymorphic stop codon in BRCA2. Nature Genet 14: 253-254, 1996.
211. McAllister K, Haugen-Strano A, Hagevik S, Brownlee H, Collins N, Futreal P, Bennett LM, and Wiseman R. Characterization of the rat and mouse homologues of the BRCA2 breast cancer susceptibility gene. Cancer Res 57: 3121-3125, 1997.
212. Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C, and Frank TS. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet 9: 439-443, 1995.
213. Meza JE, Brzovic P, King M, and Klevit R. Mapping the functional domains of BRCA1. Interaction of the ring finger domains of BRCA1 and BARD1. J Biol Chem 274: 5659-5665, 1999.
214. Mies C. Recurrent secretory carcinoma in residual mammary tissue after mastectomy. Am J Surg Pathol 17: 715-721, 1993.
215. Miki Y, Katagiri T, Kasumi F, Yoshimoto T, and Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nature Genet 13: 245-247, 1996.
216. Miki Y, Swensen J, Shattuck-Eidens D, Futreal P, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett L, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattlier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Wark J, Tonin P, Narod S, Bristow P, Norris F, Helvering L, Morrison P, Rosteck P, Lai M, Barrett J, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, and Skolnick M. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994.
217. Milner J, Ponder B, Highes-Davies L, Seltmann M, and Kouzarides T. Transcriptional activation functions in BRCA2. Nature 386: 772-773, 1997.
218. Montagna M, Santacatterina M, Torri A, Menin C, Zullato D, Chicco-Bianchi L, and D’Adnrea E. Identification of a 3kb Alu-mediated BRCA1 gene rearrangement in two breast/ovarian cancer families. Oncogene 18: 4160-4165, 1999.
219. Monteiro AN, August A, and Hanafusa H. Evidence for a transcriptional activation function of BRCA1 C-terminal region. Proc Natl Acad Sci USA 93: 13595-13599, 1996.
220. Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Bruner J, and Narod S. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66: 1259-1272, 2000.
221. Moynahan M, Chiu J, Koller B, and Jasin M. Brca 1 controls homology-directed DNA repair. Mol Cell 4: 511-518, 1999.
222. Nakajima T, Uchida C, Anderson S, Lee C, Hurwitz J, Parvin J, and Montminy M. RNA helicase A mediates association of CBP with RNA polymerase II. Cell 90: 1107-1112, 1997.
223. Narod S, Feunteun J, Lynch H, Watson P, Conway T, Lynch J, and Lenoir G. Familial breast-ovarian cancer locus on chromosome 17q12-q23. Lancet 338: 82-83, 1991.
224. Narod S, Ford C, Devilee P, Barkardottir R, Lynch H, Smith S, Ponder B, Wever B, Garber J, Birch J, Cornelis R, Kelsell D, Spurr N, Smyth E, Haites N, Sobol H, Bignon Y, ChangClaude J, Hamann U, Lindblom A, Borg A, Piver MS, Gallion H, Struewing J, Whittemore A, Tonin P, Goldgar D, Easton D, and BCLC. An evolution of genetic heterogeneity in 145 breast-ovarian cancer families. Breast Cancer Linkage Consortium. Am J Hum Genet 56: 254-264, 1995.
225. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Burnet JS, Ponder A, and HOCCSG. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 339: 424-428, 1998.
226. Nelen MR, van Staveren WC, Peeters EA, Hassel MB, Gorlin RJ, Hamm H, Lindboe CF, Fryns JP, Sijmons RH, Woods DG, Mariman EC, Padberg GW, and Kremet H. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Mun Mol Genet 6: 1383-1387, 1997.
227. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, Borgen P, Brown K, Skolnick M, Shattuck-Eidens D, Jhanwar S, Goldgar D, and Offit K. Recurrent BRCA2 6147delT mutations in Ashkenazi Jewish women affected by breast cancer. Nature Genet 13: 126-128, 1996.
228. Neuhausen SL, Godwin AK, Gershoni-Baruch R, Schubert E, Garber J, Stoppa-Lyonnet D, Olah E, Csokay B, Serova O, Lalloo F, Osorio A, Stratton M, Offit K, Boyd J, Caligo MA, Scott RJ, Schofield A, Teugels E, Schwab M, Cannon-Albright L, Bishop T, Easton D, Benitez J, King M-C, Ponder BAJ, Weber B, Devilee P, Borg A, Narod SA, and Goldgar D. Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 62: 1381-1388, 1998.
229. Newill V. Distribution of cancer mortality among ethnic subgroups of the white population of New York City, 1953-58. J Natl Cancer Inst 26: 405-417, 1961.
230. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, and King M-C. Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 2779: 915-921, 1998.
231. Nickerson D, Tobe V, and Taylor S. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescent-based resequencing. Nucleic Acids Res 25: 2745-2751, 1997.
232. Nordling M, Karlsson P, Wahlstrom J, Engwall Y, Wallgren A, and Martinsson T. A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Res 58: 1372-1375, 1998.
233. Oddoux C, Struewing JP, Clayton CM, SN, Brody LC, Kaback M, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, and Offit K. The carrier frequency of the BRCA2 617delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nature Genet 14: 188-190, 1996.
234. Oefner P and Underhill P. Comparative DNA sequencing by denaturing high-performance liquid chromatography (DHPLC). Am J Hum Genet 57: A266, 1995.
235. Ogryzko V, Schiltz R, Russanova V, Howard B, and Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953-959, 1996.
236. Oleykowski C, Bronson Mullins C, Godwin A, and Yeung A. Mutation detection using a novel plant endonuclease. Nucleic Acids Res 26: 4597-4602, 1998.
237. Ouchi T, Monteiro ANA, August A, Aaronson SA, and Hanafusa H. BRCA1 regulates p53-depen-dent gene expression. Proc Natl Acad Sci USA 95: 2302-2306, 1998.
238. Pao GM, Janknecht R, Ruffner H, Hunter T, and Verma IM. CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc Natl Acad Sci USA 97: 1020-1025, 2000.
239. Parkin D and Iscovich J. Risk of cancer in migrants and their descendants in Israel: II carcinomas and germ-cell tumours. Int J Cancer 70: 654-660, 1997.
240. Patel K, Yu V, Lee H, Corcoran A, Thistlethwaite F, Evans M, Colledge W, Friedman L, Ponder B, and Venkitaraman A. Involvement of Brca2 in DNA repair. Mol Cell 1: 347-357, 1998.
241. Paul T, Rogakou E, Yamazaki V, Kirchgessner C, Gellert M, and Bonner W. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 10: 886-895, 2000.
242. Payne S, Newman B, and King MC. Complex germline rearrangement of BRCA1 associated with breast and ovarian cancer. Genes Chromosomes Cancer 29: 58-62, 2000.
243. Peelen T, van Vliet M, Petrij-Bosch A, Mieremet R, Szabo C, van den Ouweland AMW, Hogervorst F, Brohet R, Ligtenberg MJL, Teugels E, van der Luijt R, van der Hout AH, Gille JJP, Pals G, Jedema I, Olmer R, van Leeuwen I, Newman B, Plandsoen M, van der Est M, Brink G, Hageman S, Arts PJW, Bakker MM, Willems HW, van der Looij E, Neyns B, Bonduelle M, Jansen R, Oosterwijk JC, Sijmons R, Smeets HJM, van Asperen CJ, Meijers-Heijboer H, Klijn JGM, de Greve J, King M-C, Menko FH, Brunner HG, Halley D, van Ommen G-JB, Vasen HFA, Cornelisse CJ, van’t Veer LJ, de Knijff P, Bakker E, and Devilee P. A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families. Am J Hum Genet 60: 1041-1049, 1997.
244. Peltomaki P and Vasen H. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 113: 1146-1158, 1997.
245. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedau M, Hogervorst FFL, Hage-man S, Arts PJW, Ligtenberg MJL, Meijers-Heijboer H, Klijn JGM, Vasen HFA, Cornelisse CJ, van’t Veer LJ, Bakker E, van Ommen G-JB, and Devilee P. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nature Genet 17: 341-345, 1997.
246. Petrukhin L, Dangel J, Vanderveer L, Costalas J, Bellacosa A, Grana G, Daly M, and Godwin AK. The I1307KAPC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breast-ovarian cancer kindreds. Cancer Res 57: 5480-5484, 1997.
247. Petty E and Dilleen A. BRCA1 mutation testing: controversies and challenges. Clin Chem 43: 68, 1997.
248. Phelan C, Rebbeck R, Weber B, Devilee P, Ruttledge M, Lynch H, Lemoir G, Statton M, Easton D, Ponder B, Cannon-Albright L, Larsson C, Goldgar D, and Narod S. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (ANTR) locus. Nature Genet 12: 309-311, 1996.
249. Pisano M, Cossu A, Persico I, Palmieri G, Angius A, Casu G, Palomba G, Sarobba M, Rocca P, Dedola M, Olmeo N, Pasca A, Budroni M, Marras V, Pisano A, Pfarris A, Massarelli G, Pirastur M, and Tanda F. Identification of a founder BRCA2 mutation in Sardinia. Br J Cancer 82: 553-559, 2000.
250. Piver M, Jishi M, Rsudada Y, and Nava G. Primaty peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: A report of the Gilda Radner Familial Ovarian Cancer Registry. Cancer 71: 2751-2755, 1993.
251. Plub A, Zu J, Reddy G, Bolub E, and Ashley T. Presynaptic association of Rad51 protein with selected sites in meiotic chromatin. Proc Natl Acad Sci USA 93: 5920-5924, 1996.
252. Powles T, Jones A, Ashley S, O’Brien M, Tidy V, Treleavan J, Cosgrove D, Nach A, Sacks N, Baum M, McKinna J, and Davey J. The Royal Marsden Hospital pilot tamoxifen chemoprev-ention trial. Breast Cancer Res Treat 31: 73-82, 1994.
253. Presneau N, LaPlace-Marieze V, Sylvain V, Lortholary A, Hardouin A, Bernard-Gallon D, and Bignon YJ. Mutation by deletion-insertion in BRCA-1 gene in three unrelated French breast/ovarian cancer families: possible implication of a mobile element (in French). Bull Cancer 86: 385-390, 1999.
254. Puget N, Torchard D, Serova-Sinilnikova OM, Lynch HT, Feunteun J, Lenoir GM, and Mazoyer S. A 1-kb Alu-mediated germ-line deletion removing BRCA1 exon 17. Cancer Res 57: 828-831, 1997.
255. Puget N, Stoppa-Lyonnet D, Sinilnikova OM, Pages S, Lynch HT, Lenoir GM, and Mazoyer S. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res 59: 455-461, 1999a.
256. Puget N, Sinilnikova OM, Stoppa-Lyonnet D, Audoynaud C, Pages S, Lynch HT, Goldgar D, Lenoir GM, and Mazoyer S. An Alu-mediated 6-kb duplication in the BRCA1 gene: a new frontier mutation? Am J Hum Genet 64: 300-302, 1999b.
257. Radding C. Helical interactions in homologous pairing and strand exchange driven by RecA protein. J Biol Chem 266: 5355-5358, 1991.
258. Radford DM and Zehnbauer BA. Inherited breast cancer. Surg Clin North Am 76: 205-220, 1996.
259. Rajan JV, Wang M, Marquis ST, and Chodosh LA. BRCA2 is coordinately regulated with BRCA1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci USA93: 13078-13083, 1996.
260. Rajan JV, Marquis ST, Gardner HP, and Chodosh LA. Developmental expression of BRCA2 colocalizes with BRCA1 and is associated with proliferation and differentiation in multiple tissues. Dev Biol 184: 385-401, 1997.
261. Ramus S, Friedman L, Gayther S, Ponder B, Bobrow L, van der Looji M, Papp J, and Olah E. A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. Nature Genet 15: 14-15, 1997.
262. Ravnik-Glavac D and Dean M. Sensitivity of single-strand conformation polymorphism and heteroduplex method for mutation detection in the cystic fibrosis gene. Hum Mol Genet 3: 801-807, 1994.
263. Rebbeck T. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 6: 733-743, 1997.
264. Rebbeck T, Walker A, Hosknon K, Phelan C, Narod S, Garber J, and Weber B. Modifications of familial breast cancer penetrance by glutathione-S-transferase genotypes. Am J Hum Genet57: A4, 1995.
265. Rebbeck T, Blackwood MA, Walker A, White D, Godwin A, Daly M, Garber A, Weber B, and Narod S. Association ofbreast cancer incidence with NAT2 genotype and smoking in BRCA1 mutation carriers. Am J Hum Genet 61: A46, 1997.
266. Rebbeck TR, Kantoff PA, Krithivas K, Godwin AK, Daly MB, Narod SA, Garber JE, Weber BL, and Brown M. Modification of BRCA1-associated breast cancer penetrance by androgen receptor CAG repeat length variants. Am J Hum Genet 64: 1371-1377, 1999a.
267. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA, Neuhausen SL, Lynch HT, and Weber BL. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91: 1475-1479, 1999b.
268. Redston M, Nathanson KL, Yean ZQ, Neuhausen SL, Satagopan J, Wong N, Yang D, Nafa D, Abrahamson J, Ozcelik H, Antin-Ozerkis D, Andrulis I, Daly M, Pinsky L, Schrag D, Gallinger S, Kaback M, King MC, Woodage T, Brody LC, Godwin A, Warner E, Weber B, Foulkes W, and Offit K. The APC I1307K allele and breast cancer risk. Nature Genet 20: 13-14, 1998.
269. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI, and Boyd J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res57: 3657-3659, 1997.
270. Rice C and Futscher B. Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res 28: 3233-3239, 2000.
271. Rice J, Ozcelik H, Maxeiner P, Andrulis I, and Futscher B. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21: 1761-1765, 2000.
272. Richter S and Seth A. One step direct detection of recurrent mutations in the breast cancer susceptibility gene BRCA1. Int J Oncol 12: 1263-1267, 1998.
273. Ries L, Kosary C, Hankey B, Harras A, Miller B, Edwards B, and editors SEER cancer statistics reviews 1973-1993. Bethesda, MD: National Cancer Institute, 1996, pp 30-56.
274. Risinger J, Barrett J, Watson P, Lynch H, and Boyd J. Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer 77: 1836-1843, 1996.
275. Roa B, Boyd A, Volcik K, and Richards C. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature Genet 14: 185-187, 1996.
276. Rohlfs E, Puget N, Graham M, Weber B, Garber J, Skrzynia C, Halperin J, Lenoir G, Silverman L, and Mazoyer S. An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer 28: 300-307, 2000.
277. Rothfub A, Schutz P, Bochum S, Volm T, Eberhardt E, Kreienberg R, Vogel W, and Speit G. Induced micronucleus frequencies in peripheral lymphocytes as a screening test for carriers of a BRCA1 mutation in breast cancer families. Cancer Res 60: 390-394, 2000.
278. Ruffner H and Verma IM. BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc Natl Acad Sci USA 94: 7138-7143, 1997.
279. Ruffner H, Jiang H, Craig A, Hunter T, and Verman I. BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. Mol Cell Biol 19: 4843-4854, 1999.
280. Sakorafas GH: Breast Cancer. Athens, Greece: Lagos Medical Publications, 1999, p 1.
281. Sakorafas GH and Tsiotou AG. Genetic predisposition to breast cancer: a surgical perspective. Br J Surg 87: 149-162, 2000.
282. Salber E, Trichopulos D, and MacMahon B. Lactation and reproductive histories of breast cancer patients in Boston, 1965-66. J Natl Cancer Inst 43: 1013-1024, 1969.
283. Sali A and Blundell T. Comparative protein modeling by satisfaction of spatial restraints. J Mol Biol 234: 779-815, 1993.
284. Schrag D, Kuntz KM, Garber JE, and Weeks JC. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 336: 1465-1471, 1997.
285. Schrag D, Kuntz KM, Garber JE, and Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 283: 617-624, 2000.
286. Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, and Livingston DM. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90: 425-435, 1997a.
287. Scully R, Ganesan S, Brown M, DeCaprio JA, Cannistra SA, Feunteun J, Schnitt S, and Livingston DM. Location of BRCA1 in human breast and ovarian cancer cells. Science 272: 123-126, 1996.
288. Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM, and Parvin JD. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci USA 94: 5605-5610, 1997b.
289. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, and Livingston DM. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88: 265-275, 1997c.
290. Seitz S, Rohde K, Bender E, Nothnagel A, Pidde H, Ullrich O, El-Zehairy A, Haensch W, Jandrig B, Kilble K, Schlag P, and Scherneck S. Deletion mapping and linkage analysis provide strong indication for the involvement of the human chromosome region 8p 12-22 in breast carcinogenesis. Br J Cancer 76: 983-991, 1997.
291. Serova O, Montagna M, Torchard D, Narod S, Tonin P, Sylla B, Lynch H, Feunteun J, and Lenoir G. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. Am J Hum Genet 58: 42-51, 1996.
292. Serova O, Mazoyer S, Puget N, Dubois V, Tonin P, Shugart Y, Goldgar D, Narod S, Lyncj H, and Lenoir G. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer susceptibility genes? Am J Hum Genet 60: 486-495, 1997.
293. Sharan S, Wims M, and Bradley A. Murine Brca1: sequence and significance for human missense mutations. Hum Mol Genet 3: 2275-2278, 1995.
294. Sharan SK, Morimatsu M, Albrecht U, Lim D-S, Regel E, Dinh C, Sands A, Eichele G, Hasty P, and Bradley A. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 386: 804-810, 1997.
295. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla L, Erdos M, Brody L, Friedman L, Ostermeyer E, Szabo C, King M-C, Jhanwar S, Offit K, Norton L, Gilewski T, Lubin M, Osborne M, Black D, Boyd M, Steel M, Ingles S, Haile R, Lindblom A, Olsson H, Borg A, Bishop DT, Solomon E, Radice P, Spatti G, Gayther S, Ponder B, Warren W, Stratton M, Liu Q, Fujimura F, Lewis C, Skolnick MH, and Goldgar DE. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. JAMA 273: 535-541, 1995.
296. Shen D, Wu Y, Subbarao M, Bhat H, Chillar R, and Vadgama J. Mutation analysis of BRCA1gene in African-American patients with breast cancer. J Natl Med Assoc 92: 29-35, 2000.
297. Sherr CH and Roberts JM. Inhibitors of mammalian G1 cyclic-dependent kinases. Genes Dev 9: 1149-1163, 1995.
298. Shieh S, Ahn J, Tamai K, Taya Y, and Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) prosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14: 289-300, 2000.
299. Shih H, Nathanson KL, Seal S, Collins N, Stratton M, Rebbeck T, and Weber B. BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers. Clin Cancer Res6: 4259-4264, 2000.
300. Shinohara A, Ogawa H, and Ogawa T. Rad51 protein involved in repair and recombination in Saccharomyces cerevisiae is a recA-like protein. Cell 69: 457-470, 1992.
301. Sidransky D, Tokino T, Helzlsoure K, Zehnbauer B, Rausch G, Shelton B, Prestigiacomo L, Bo-gelstein B, and Davidson N. Inherited p53 gene mutations in breast cancer. Cancer Res 52: 2984-2986, 1992.
302. Sigurdsson S, Thorlacius S, Tomasson J, Tryggvadottir L, Benediktsdottir K, Eyfjord JE, and Jons-son E. BRCA2 mutation in Icelandic prostate cancer patients. J Mol Med 75: 758-761, 1997.
303. Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Leblanc JF, Belanger C, Dion F, Liu Q, Skolnick M, Goldgar D, Shattuch-Eidens D, Labrie F, and Narod SA. Common origins ofBRCA1 mutations in Canadian breast and ovarian cancer families. Nature Genet 8: 392-398, 1994.
304. Sinclair C, Berry R, Schaid D, Thibodeau S, and Couch F. BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 60: 1371-1375, 2000.
305. Sinilnikova OM, Egan KM, Quinn J, Boutrand L, Lenoir G, Stoppa-Lyonnet D, Desjardins L, Levy C, Goldgar D, and Gragoudas E. Germline brca2 sequence variants in patients with ocular melanoma. Int J Cancer 82: 325-328, 1999.
306. Snouwaert JN, Gowen LC, Latour AM, Mohn AR, Xiao A, DiBiase L, and Koller BH. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. Oncogene 18: 7900-7907, 1999.
307. Sobol H, Birnbaum D, and Eisinger F. Evidence for a third breast-cancer susceptibility gene. Lancet 344: 1151-1152, 1994.
308. Somasundaram K, Zharn H, Zeng Y, Houvras Y, Peng Y, Zhang H, Wu G, Licht J, Weber B, and El-Diery W. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature 389: 187-190, 1997.
309. Soussi T, Caron de Fromentel C, and May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5: 945-952, 1990.
310. Southern E. DNA chips: analysing sequence by hybridization to oligonucleotides on a large scale. Trends Genet 12: 110-115, 1996.
311. Spillman MA and Bowcock AM. BRCA1 and BRCA2 messenger-RNA levels are coordinately elevated in human breast-cancer cells in response to estrogen. Oncogene 13: 1639-1645, 1996.
312. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, and Tavtigian SV. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet 15: 356-362, 1997.
313. Stratton MR. Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet 5: 1515-1519, 1996.
314. Struewing J, Tarone R, Broday L, Li F, and Boice J. BRCA1 mutations in young women with breast cancer. Lancet 347: 1493, 1996.
315. Struewing J, Watson P, Easton D, Ponder B, Lynch H, and Tucker M. Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monograph 17: 33-35, 1995a.
316. Struewing J, Abeliovish D, Peretz T, Avishai N, Kaback M, Collins F, and Brody L. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature Genet 11: 198-200, 1995b.
317. Struewing J, Hartge P, Wacholder S, Baker S, Berlin M, McAdams M, Timmerman M, Brody L, and Tucker M. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-1408, 1997.
318. Sung P. Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast Rad51 protein. Science 265: 1241-1243, 1994.
319. Sung P and Robberson D. DNA strand exchange mediated by a Rad51-ssDNA nucleoprotein filament with polarity opposite to that of RecA. Cell 82: 453-461, 1995.
320. Suzuki A, de la Pompa JL, Hakem R, Elia A, Yoshida R, Mo R, Nishina H, Chuang T, Wakeham A, Itie A, Koo W, Billia P, Ho A, Fukumoto M, Hui CC, and Mak TW. Brca2 is required for embryonic cellular proliferation in the mouse. Genes Dev 11: 1242-1252, 1997.
321. Swensen J, Hoffman M, Skolnick MH, and Neuhausen SL. Identification of a 14 kb deletion involving the promoter region of BRCA1 in a breast cancer family. Hum Mol Genet 6: 1513-1517, 1997.
322. Taioli E, Bradlow H, Garbers S, Sepkovic D, Osborne M, Trachman J, Ganguly S, and Garte S. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev 23: 232-237, 1999.
323. Tashiro S, Kogomura N, Shinohara A, Tanaka K, Ueda K, and Kamada N. S-phase specific formation of the human Rad51 protein nuclear foci in lymphocytes. Oncogene 12: 2165-2170, 1996.
324. Tavitigian S, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc J, Mitchell J, McArthur-Morrison J, Nguyen K, Peng Y, Samson C, Schroeder M, Snyder S, Steele L, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thomas A, Tran T, Tran T, Tranchant M, Weaver-Feldhans J, Wond AKC, Shizuya H, Eyfjord J, Cannon-Albright L, Labrie F, Skolnick M, Weer B, Kamb A, and Goldgar D. The complete BRCA2 gene and mutations in chromosomes 13q-linked kindreds. Nature Genet 12: 333-337, 1996.
325. Teng D, Bogden R, Baumgard M, Bell R, Berry S, Davis R, Ha P, Kehrer R, Jammulapati S, Chen Q, Offit K, Skolnick M, Tavtigian S, Jhanwar S, Swedlund B, Wond A, and Kanb A. Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nature Genet 13: 241-247, 1996.
326. Thakur S, Zhang H, Peng Y, Le H, Carroll B, Ward T, Yao J, Farid L, Couch F, Wilson R, and Wever B. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol 17: 444-452, 1997.
327. Thomas JE, Smith M, Tonkinson J, Rubinfeld B, and Polakis P. Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage. Cell Growth Differ 8: 801-809, 1997.
328. Thompson ME, Jensen RA, Obermiller PS, Page DL, and Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nature Genet 9: 444-450, 1995.
329. Thorlacius S, Olafsdottir GH, Tryggvadottir L, Neuhausen S, Jonasson JG, and Tavtigian S. A single mutation in the BRCA2 gene in male and female breast cancer families with varied cancer phenotypes. Nature Genet 13: 117-119, 1996.
330. Thorlacius S, Struewing J, Hartge P, Olafsdottir G, Sigvaldason H, Tryggvadottir L, Wacholder S, Tulinius H, and Eyfjord J. Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet 352: 1337-1339, 1998.
331. Tibbetts R. Functional interactions between BRCA1 and the checkpoint kinase ATR during geno-toxic stress. Genes Dev 14(23): 2989-3002, 2000.
332. Tirkkonen M, Kainu T, Loman N, Johannsson O, Olsson H, Barkardottir R, Kallioniemi O, and Borg A. Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. Genes Chromosomes Cancer 24: 56-61, 1999.
333. Tobacman J, Greene M, Tucker M, Costa J, Kase R, and Fraumeni J. Intra-abdominal carcinomatosis after prophylactic oophorectomy in ovarian cancer-prone families. Lancet 2: 795-797, 1982.
334. Tominaga K, Morisaki H, Kaneko Y, Fujimoto A, Tanaka T, Ohtsubo M, Hirai MHO, Ikeda K, and Nakanishi M. Role of human Cds1 (Chk2) kinase in DNA damage checkpoint and its regulation by p53. J Biol Chem 274: 1463-1467, 1999.
335. Tomlinson I and Houlston R. Peutz-Heghers syndrome. J Med Genet 34: 1007-1011, 1997.
336. Tonin P. Genes implicated in hereditary breast cancer syndromes. Semin Surg Oncol 18: 281-286, 2000.
337. Tonin P, Moslehi R, Green R, Rosen B, Cole D, Boyd N, Cutler C, Margolese R, Carter R, McGillivray B, Ives E, Labrie F, Gilchrist D, Morgan D, Simard J, and Narod S. Linkage analysis of 26 Canadian breast and breast-ovarian cancer families. Hum Genet 95: 545-550, 1995a.
338. Tonin P, Weber B, Offit K, Couch F, Rebeck T, Neuhausen S, Godwin AK, Daly M, Costalas J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Haber D, Struewing J, Warner E, Rosen B, Foulkes W, Lerman C, Pechkin B, Serova O, Lynch HT, Lenoir GM, Narod SA, and Garber JE. A high frequency of BRCA1 and BRCA2 mutations in 222 Ashkenazi Jewish breast cancer families. Nature Med 2: 1179-1183, 1996.
339. Tonin R, Serova O, Lenoir G, Lynch H, Durocher F, Simard J, Morgen K, and Narod S. BRCA1 mutations in Ashkenazi Jewish women. Am J Hum Genet 57: 189, 1995b.
340. Tsuzuki T, Fujii Y, Sakumi K, Tominaga, Y, Nakao K, Sekigucki M, Matsushiro A, Yoshimura Y, and Morita T. Targeted disruption of the Rad51 gene leads to lethality in embryonic mice. Proc Natl Acad Sci USA 93: 6236-6240, 1996.
341. Tulinius H, Olafsdottir G, Sigvaldason H, Tryggvadottir L, and Bjarnadottir K. Neoplastic diseases in families of breast cancer patients. J Med Genet 31: 618-621, 1994.
342. Underhill P, Jin L, Lin A, Mehdi S, Jankins T, Vollrath D, Davis R, Cavalli-Sforza L, and Oefner P. Detection of numerous Y chromosome biallelic polymorphisms by denaturing high-performance liquid chromatography. Genome Res 7: 996-1005, 1997.
343. van der Looij M, Cleton-Jansen AM, van Eijk R, Morreau H, van Vliet M, Kuipers-Dijkshoorn N, Olah E, Cornelisse CJ, and Devilee P. A sporadic breast tumor with a somatically acquired complex genomic rearrangement in BRCA1. Genes Chromosomes Cancer 27: 295-302, 2000.
344. Van Orsouw N, Dhanda R, Elhaji Y, Narod S, Li F, Eng C, and Vijg J. A highly accurate, low cost test for BRCA1 mutations. J Med Genet 36: 747-753, 1999.
345. Varley J, Evans DG, and Birch J. Li-Fraumeni syndrome-a molecular and clinical review. Br J Cancer 76: 1-14, 1997.
346. Vaughn J, Cirisano F, Huper G, Bershuck A, Futrial P, Marks J, and Iglehart J. Cell cycle control of BRCA2. Cancer Res 56: 4590-4594, 1996a.
347. Vaughn JP, Davis PL, Jarboe MD, Huper G, Evans AC, Wiseman RW, Berchuck A, Iglehart JD, Futreal PA, and Marks JR. BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells. Cell Growth Differ 7: 711-715, 1996b.
348. von Borstel R, Cain K, and Steinberg C. Mutants of yeast with enhanced spontaneous mutation rates. Genetics 60: 17-27, 1971.
349. Wallace R. DNA on a chip: serving up the genome for diagnostics and research. Mol Med Today 55: 569-574, 1997.
350. Wang A, Schneider-Broussard R, Kumar A, MacLeod M, and Johnson D. Regulation of BRCA1 expression by the Rb-E2F pathway. J Biol Chem 275: 4532-4536, 2000.
351. Wang Z-J, Churchman M, Campbell I, Zu W-H, Yan Z-Y, McCluggage W, Foulkes W, and Tomlinson I. Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours. Br J Cancer 80: 70-72, 1999.
352. Watanabe M, Shiraishi T, Muneyuki T, Nagai M, Fukutome K, Murata M, Kawamura J, and Yatani R. Allelic loss and microsatellite instability in prostate cancers in Japan. Oncology 55: 569-574, 1998.
353. Weber B. Familial breast cancer. Recent Results in Cancer Res. 140: 5-16, 1996.
354. Welcsh PL, Owens K, and King M. Insights into the functions of BRCA1 and BRCA2. Trends Genet 16: 69-74, 2000.
355. Wen W, Bernstein L, Lescallett J, Beazer-Barclay Y, Sullivan-Halley J, White M, and Press M. Comparison of TP53 mutations identified by oligonucleotide microarray and convertional DNA sequence analysis. Cancer Res 60: 2716-2722, 2000.
356. Whittemore A, Gong G, and Iitnyre J. Prevalence and contribution of BRCA1 mutations in breast cancer and ovarian cancer: results from three US population-based case-control studies of ovarian cancer. Am J Hum Genet 60: 496-504, 1997.
357. Wilson C, Ramos L, Villasenor M, Anders K, Press M, Clarke K, Karlan B, Chen J, Scully R, Livingston D, Zuch R, Kanter M, Coyhen S, Calzone F, and Slamon D. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nature Genet 21: 236-240, 1999.
358. Wong A, Pero R, Ormonde P, Tavigian S, and Bartel P. Rad51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene BRCA2. J Biol Chem272: 31941-31944, 1997.
359. Wooster R, Bignell G, and Lancaster J. Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789-792, 1995.
360. Wooster R, Newhausen S, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D, Fields P, Marchall G, Narod S, Lenoir G, Lynch H, Frunteun J, Devilee P, Cornel-isse C, Menko F, Daly PA, Ormiston W, McManus R, Pye C, Lewis C, Cannon-Albright L, Peto J, Ponder B, Skolnick M, Easton D, Goldgar D, and Stratton M. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265: 2088-2090, 1994.
361. Wu LC, Wang Z, Tsan J, Spillman M, Phung A, Zu X, Yang M, Hwang MC, Bowcock A, and Baer R. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nature Genet 14: 430-440, 1996.
362. Xu C, Chambers J, Brown M, Jujeirat Y, Mohammed S, Hodgson S, Kelsell D, Surr N, Bishop D, and Solomon E. Mutations and alternative splicing of the BRCA1 gene in UD breast/ovarian cancer families. Genes Chromosomes Cancer 18: 102-110, 1997.
363. 2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell 3: 389-395, 1999.
364. Yang Z, Ogryzko V, Nishikawa J, Howard B, and Nakatani Y. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature (London) 382: 319-324, 1996.
365. Yarden RI and Brody LC. BRCA1 interacts with components of the histone deacetylase complex. Proc Natl Acad Sci USA 96: 4983-4988, 1999.
366. Yuan ZQ, Begin LR, Wong N, Brunet JS, Trifiro M, Gordon PH, Pinsky L, and Foulkes WD. The effect of the I1307K APC polymorphism on the clinicopathological features and natural history of breast cancer. Br J Cancer 81: 850-854, 1999.
367. Zabludoff SD, Wright WW, Harchman K, and Wold B. BRCA1 messenger-RNA is expressed highly during meiosis and spermiogenesis but not during mitosis of male germ cells. Oncogene 13: 649-653, 1996.
368. Zhang X, Morera S, Bates PA, Whitehead PC, Coffer AI, Hainbucher K, Nash RA, Sternberg MJE, Lindahl T, and Freemont PS. Structure of an XRCC1 BRCT domain: a new proteinprotein interaction module. EMBO J 17: 6404-6411, 1998.